Showing results (621-630 of 674) with videos related to

Sort By:
Pageof 68
ACS Medicinal Chemistry Letters|June 16, 2022
Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 AgonistsNicholas R Wurtz, James A Johnson, Andrew Viet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast CancerJodi M Carter, Mei-Yin C Polley, Roberto A Leon-Ferre, et al.
Iscience|September 10, 2019
Convergent Evolution of Mucosal Immune Responses at the Buccal Cavity of Teleost FishYong-Yao Yu, Wei-Guang Kong, Hao-Yue Xu, et al.
Sensors (Basel, Switzerland)|December 14, 2011
Development of a stepping force analgesic meter for a rat arthritic modelMun Fei Yam, Lip Yee Por, Kok Khiang Peh, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart FailureYoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
Breast Cancer Research and Treatment|September 16, 2017
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancerRoberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, et al.
Pageof 68